Kyowa Kirin

-11.97%

Kyowa Kirin is a global specialty pharmaceutical company that focuses on research and development, manufacturing, and commercialization of prescription drugs and consumer healthcare products. The company was founded in 1949 in Tokyo, Japan as Kyowa Hakko Kogyo Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in 2008.
They have a presence in over 30 countries worldwide, with a significant presence in the United States, Europe, and Asia. Kyowa Kirin is known for its focus on rare diseases, oncology, and neuroscience, as well as for its strong research and development capabilities.
The company's mission is to contribute to the health and well-being of people around the world through innovative pharmaceutical and healthcare products. Their core values include putting patients first, promoting diversity and inclusion, and being a responsible corporate citizen.
Kyowa Kirin has a diverse portfolio of prescription drugs, over-the-counter products, and medical devices. Some of their notable products include the biologic therapies Poteligeo and Crysvita, used to treat rare diseases, and the popular gastrointestinal medicine Nexium.
In addition to its pharmaceutical business, Kyowa Kirin also has a consumer healthcare division that offers a range of self-care products, including pain relief patches, digestive health supplements, and cold and flu remedies.
The company has a strong commitment to sustainability and corporate responsibility, with initiatives focused on reducing its environmental impact, promoting gender equality and diversity, and supporting local communities through various philanthropic activities.
Overall, Kyowa Kirin is a prominent player in the pharmaceutical industry, known for its dedication to improving the lives of patients and for its strong presence in both established and emerging markets.

1. Global Presence: Kyowa Kirin has a strong global presence with operations in more than 28 countries, including Japan, the United States, and Europe. This allows the company to reach a diverse market and cater to the needs of different populations.
2. Focus on Rare Diseases: Kyowa Kirin specializes in developing and manufacturing treatments for rare diseases that have a significant unmet medical need. It is one of the few pharmaceutical companies with a strong focus on this niche area.
3. Expertise in Biologics: Kyowa Kirin is a pioneer in the development of biologic drugs, which are derived from living organisms and can have a significant impact on treating rare diseases and improving patients' lives.
4. Strong R&D Focus: The company has a robust research and development (R&D) program, with a dedicated team of scientists and researchers continually working to discover and develop new treatments for rare diseases.
5. Strategic Partnerships: Kyowa Kirin has established strategic partnerships with other pharmaceutical companies and research institutions to advance the development of new treatments for rare diseases.
6. Patient-Centric Approach: The company has a patient-centric approach, which means that it involves patients in the development and implementation of treatments from the early stages, ensuring that their needs and preferences are considered.
7. Strong Ethical Standards: Kyowa Kirin is committed to ethical standards and has a corporate philosophy of "making the health and well-being of people the first priority."
8. Sustainability Initiatives: The company is actively involved in sustainability initiatives, including reducing its carbon footprint and supporting local communities.
9. Diversified Portfolio: Kyowa Kirin has a diverse product portfolio that includes prescription drugs, over-the-counter medicines, and consumer healthcare products, allowing it to cater to the needs of different patient populations.
10. Strong Financial Performance: The company has consistently shown strong financial performance, with a focus on sustainable growth and long-term value creation for its shareholders.

Kyowa Kirin is a global specialty pharmaceutical company that focuses on developing, manufacturing, and marketing innovative medicines and healthcare products. Its business model can be defined as follows:
1. Research and Development: Kyowa Kirin invests a significant amount of resources in research and development (R&D) activities to discover and develop new drugs and therapeutic treatments. The company has a strong pipeline of potential new products in various stages of development.
2. Manufacturing: Kyowa Kirin has manufacturing facilities for pharmaceuticals, biologics, and medical devices in Japan, the United States, and Europe. The company ensures high-quality production standards and efficient supply chain management to meet the demand for its products.
3. Marketing and Sales: Kyowa Kirin's products are marketed and sold globally through its own sales teams, as well as through strategic partnerships and collaborations with other pharmaceutical companies. The company's marketing strategy focuses on building strong relationships with healthcare professionals and creating awareness about its products among patients.
4. Geographic Diversification: The company has a global presence with operations in Asia, North America, and Europe. This geographic diversification helps Kyowa Kirin mitigate risks associated with regional economic and political factors, as well as benefit from the growing demand for healthcare products in different regions.
5. Therapeutic Focus: Kyowa Kirin has expertise in developing medicines and treatments in four main therapeutic areas: nephrology, oncology, immunology/allergy, and central nervous system disorders. This focus allows the company to leverage its scientific knowledge and resources to create highly effective products in these areas.
6. Collaborative Approach: Kyowa Kirin collaborates with academic institutions, research organizations, and other biopharmaceutical companies to share knowledge, expertise, and resources in R&D. This collaborative approach helps the company accelerate drug discovery and development processes.
7. Corporate Social Responsibility: Kyowa Kirin is committed to being a socially responsible company. It aims to improve access to healthcare and contribute to society through various initiatives, such as patient assistance programs, disease awareness campaigns, and sustainable business practices.
In summary, Kyowa Kirin's business model combines a strong focus on R&D and manufacturing with a global market presence, strategic partnerships, and a commitment to corporate social responsibility. This approach allows the company to develop and provide innovative healthcare products to meet the needs of patients and healthcare professionals worldwide.

• Kyowa Kirin is a Japanese pharmaceutical company that was founded in 1949.
• The company’s name comes from a combination of its original founders’ surnames, Kyowa and Kirin.
• The company’s first product was a digestive enzyme supplement made from bitter melon extract.
• In 1953, Kyowa Kirin expanded internationally by opening a subsidiary in New York City called Kyowa Pharmaceutical, Inc.
• The company developed Japan’s first human myeloma cell line for antibody production, which is still used in research and development today.
• In the 1970s, Kyowa Kirin was one of the first companies to develop a non-steroidal anti-inflammatory drug (NSAID) called loxoprofen.
• The company is a leader in biopharmaceuticals and has been involved in the development of multiple antibody and peptide-based therapies.
• Kyowa Kirin has a strong global presence, with subsidiaries and offices in over 30 countries.
• The company focuses on research and development in areas such as oncology, nephrology, immunology, and rare diseases.
• In addition to pharmaceuticals, Kyowa Kirin also produces and markets medical devices, biosimilars, and over-the-counter products.
See Company Due Diligence: